BIOLASE, Inc. (BIOL)
-NasdaqCM | Prev Close: | 3.98 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.63 |
|---|
| Beta: | 2.54 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.47 - 6.03 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 458,848 |
|---|
| Market Cap: | 126.31M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BIOLASE Added to Two Major Indices for 2013Marketwired(Mon, Jun 17)
- Coverage initiated on Biolase by WallachBethBriefing.com(Sun, Jun 16)
- BIOLASE Adds Two New Independent Directors to Its BoardMarketwired(Mon, Jun 10)
- BIOLASE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal OfficerEDGAR Online(Mon, Jun 10)
- BIOLASE Names Current Director Alexander K. Arrow President and Chief Operating OfficerMarketwired(Fri, Jun 7)
- BIOLASE Holds Annual Meeting of ShareholdersMarketwired(Fri, Jun 7)
- BIOLASE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Thu, Jun 6)
- BIOLASE, Inc. Responds to Shareholder InquiriesMarketwired(Thu, Jun 6)
- These Micro-cap Stocks Are Surging -- And Still Have 50% to 100% UpsideStreetAuthority Network(Thu, May 30)
- BIOLASE Issued Broad New Patent for Treating Eye Conditions, Including Presbyopia, Cataracts, and GlaucomaMarketwired(Wed, May 29)
- BIOLASE, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 29)
- BIOLASE to Present at Stifel, Nicolaus & Company 2013 Jaws & Paws ConferenceMarketwired(Thu, May 23)
- BIOLASE Declares Stock Dividend for 2013 Second QuarterMarketwired(Tue, May 21)
- BIOLASE, INC FinancialsEDGAR Online Financials(Fri, May 17)
- Finding Investment Opportunities in Quality Growth Health Care Companies That the Rest of the Market is OverlookingWall Street Transcript(Fri, May 17)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| BIOL | 0.00% | 126.31M |
| BAX | 0.00% | 38.41B |
| COV | 0.00% | 31.02B |
| CSRT.L | 0.38% | 227.56M |
| BDX | 0.00% | 19.50B |
Key Statistics
| Forward P/E (1 yr): | 33.17 |
|---|
| P/S (ttm): | 2.08 |
|---|
| Ex-Dividend Date: | 24-Jun-05 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.05 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -5.31 |
|---|
Business Summary
BIOLASE, Inc., a biomedical company, develops, manufactures, and markets lasers in dentistry and medicine in the Unites States and internationally. The company offers Waterlase systems for cutting soft and hard tissue; and diode laser systems, whi...
View More